When you leave a major pharmaceutical company to start your own biotech, you'd better bring some serious credentials. Cao Guoqing has those in spades, and now his six-year-old venture is looking to prove that scientific pedigree can translate into stock market success.

Ming Yu Pharmaceutical Ltd. has filed for a Hong Kong IPO, riding a wave of biotech optimism that saw Hengrui Pharma (600276.SH; 1276.HK) shares warmly received earlier this year. The connection isn't coincidental - Cao spent years as Hengrui's vice president of biologics research before striking out on his own in 2018. Morgan Stanley, BofA Securities and CITIC Securities are handling the offering.

The Science Behind the Story

Cao's resume reads like a greatest hits of pharmaceutical training. After earning his doctorate in the U.S., he worked in a senior role at Eli Lilly before joining Hengrui, where he oversaw antibody-based therapies and small molecule drug development. That experience shows in Ming Yu's portfolio: 13 experimental drugs targeting oncology and autoimmune diseases, with 10 already in clinical trials.

The company's focus on targeted cancer therapies - specifically antibody-drug conjugates (ADCs) and bispecific antibodies - puts it squarely in one of biotech's hottest areas. These aren't your grandfather's chemotherapy drugs. They're precision weapons designed to hunt down cancer cells while leaving healthy tissue relatively unscathed.

Take MHB036C, one of Ming Yu's flagship assets. This ADC targets the TROP-2 protein found on solid tumors, and the company is testing it in combination with a PD-1/VEGF bispecific antibody for non-small cell lung cancer and breast cancer. Both diseases affect massive patient populations, which means massive potential markets. A study commissioned for the IPO application projects the global TROP-2 ADC market will explode from $1.5 billion in 2024 to $42.5 billion by 2035. That's a compound annual growth rate of 35.4%.

Show Me the Money

Ming Yu isn't just banking on future potential. The company has already demonstrated that its science has commercial value. In March, it struck a deal with Qilu Pharmaceutical for the rights to develop and launch MHB088C - another ADC targeting small-cell lung cancer - in Greater China. The partnership is worth up to 1.35 billion yuan ($190 million), including an upfront payment of 280 million yuan. That deal generated Ming Yu's entire 264 million yuan in revenue for the first half of 2025.

The autoimmune side of the business is equally promising. MHB018A, an antibody treatment for thyroid eye disease, has reached Phase Three trials. This injection blocks inflammation through the IGF-1R receptor and showed impressive results in Phase Two trials, achieving an 81% response rate against proptosis - the unsettling condition where eyes bulge from their sockets.

Then there's MH004, a drug that blocks Janos kinase (JAK) enzymes linked to inflammation. Ming Yu applied this year to register it as a treatment for mild to moderate atopic dermatitis and expects regulatory approval in the second half of 2026. According to China Insights Consultancy, the global market for atopic dermatitis therapies is forecast to expand from $14.9 billion in 2024 to $9.5 billion by 2035, with China projected to see even faster growth. The drug could also tackle other autoimmune skin disorders, including vitiligo.

The Cash Burn Reality

Here's where things get complicated. Ming Yu is bleeding cash like most pre-commercial biotechs. R&D spending totaled 182 million yuan in 2023, jumped to 281 million yuan in 2024, and hit 98 million yuan in just the first half of 2025. Net losses over those periods: 137 million yuan, 283 million yuan and 167 million yuan respectively. Add it up and you get 587 million yuan in losses over two and a half years.

The good news? Ming Yu has attracted serious money. Investors including OrbiMed, Qiming Venture Partners, Hua An Fund Management, Tigermed, IDG Capital, Oriza Holdings and 5Y Capital have participated across five funding rounds. The most recent financing in July 2025 was jointly led by OrbiMed and Qiming, with participation from existing shareholder TF Capital. That round raised $131 million and valued the company at 3.94 billion yuan.

The Competition Conundrum

But blue-chip backing doesn't guarantee smooth sailing. Ming Yu still needs to build a full-scale commercial team, and here's the awkward part: some of its key drugs will compete directly with products from Hengrui, the very company its founder left behind.

Ming Yu's atopic dermatitis treatment, MH004, would go head to head with Hengrui's ruxolitinib cream, which is also under regulatory review. In oncology, MHB036C faces off against Hengrui's TROP-2 ADC candidate SHR-A192, with both targeting non-small cell lung cancer and undergoing Phase One or Two trials. Add in multinational heavyweights like Daiichi Sankyo, AstraZeneca and Gilead Sciences crowding into the same TROP-2 space, and you've got a seriously competitive landscape.

What Success Looks Like

A successful Hong Kong listing would accomplish two critical goals. First, it would generate the funding Ming Yu needs to keep pushing its pipeline forward. Second, it would strengthen the company's negotiating position for future licensing deals. Consider GenFleet Therapeutics (2595), another oncology and autoimmune drug developer that listed in Hong Kong this September. It now commands a market capitalization of around HK$10.4 billion.

With a solid clinical pipeline and a well-regarded team, Ming Yu could potentially achieve a premium over its pre-IPO valuation of 3.94 billion yuan. That said, translating research into commercial returns represents a major test. The company has the science and the backing, but it still needs to prove it can navigate regulatory hurdles, build commercial capabilities, and carve out market share from entrenched competitors.

For investors, the question isn't whether Ming Yu has promising science - it clearly does. The question is whether promising science, even led by a former industry insider with heavyweight backing, can overcome the brutal economics of biotech competition. The Hong Kong listing will provide the capital to find out. What happens next will determine whether Ming Yu becomes another biotech success story or just another cautionary tale about the gap between laboratory promise and marketplace reality.